BiologicalDrug
Lintuzumab clinical trials
Also written SGN-33.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 1996
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
7 studies that test it; most in 1996 (1)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 1999 | 1 |
| 2001 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 4
Seagen Inc. (3) · Memorial Sloan Kettering Cancer Center (1) · Alison Walker (1) · Jonsson Comprehensive Cancer Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lintuzumab is read from its arms, and is right about nine times in ten.
Testing it · 7
- Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic SyndromesTerminatedPhase 2Alison WalkerNCT00997243Written as lintuzumab
- A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AMLCompletedPhase 2Seagen Inc.NCT00528333Written as Lintuzumab (SGN-33)
- A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedPhase 1Seagen Inc.NCT00283114Written as lintuzumab
- Monoclonal Antibody in Treating Patients With Acute Myelogenous LeukemiaStatus unknownPhase 2Jonsson Comprehensive Cancer CenterNCT00006084Written as lintuzumab
- Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous LeukemiaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00002890Written as lintuzumab
- Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic SyndromeWithdrawnPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT00003984Written as lintuzumab
- A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)CompletedPhase 1Seagen Inc.NCT00502112Written as lintuzumab
Codes
What other systems call lintuzumab · ClinicalTrials.gg INT004560
- MeSH (NLM) C477390lintuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) V00Y10W60WLINTUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3833129lintuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1716LintuzumabOne source FDA
- DrugBank DB14877One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C477390 | lintuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | V00Y10W60W | LINTUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3833129 | lintuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1716 | Lintuzumab | One source FDA |
| DrugBank | DB14877 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.